|
|
Volumn 99, Issue 18, 2007, Pages 1362-1364
|
|
Gene mutation revelation points to new target for myeloma treatment, studies say.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BORONIC ACID DERIVATIVE;
BORTEZOMIB;
I KAPPA B KINASE;
IKBKB PROTEIN, HUMAN;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
PYRAZINE DERIVATIVE;
TRAF3 PROTEIN, HUMAN;
TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;
UNCLASSIFIED DRUG;
ARTICLE;
DRUG ANTAGONISM;
DRUG EFFECT;
GENETICS;
HUMAN;
MULTIPLE MYELOMA;
MUTATION;
SIGNAL TRANSDUCTION;
ANTINEOPLASTIC AGENTS;
BORONIC ACIDS;
HUMANS;
I-KAPPA B KINASE;
MULTIPLE MYELOMA;
MUTATION;
NF-KAPPA B;
PYRAZINES;
SIGNAL TRANSDUCTION;
TNF RECEPTOR-ASSOCIATED FACTOR 3;
|
|
EID: 34748830337
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djm164 Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
